NICE Recommends Midostaurin for FLT3+ AML

May 4, 2018 – The National Institute for Health and Care Excellence (NICE) has authorized the use of midostaurin in combination with standard chemotherapy for the treatment of patients with newly diagnosed FLT3-positive acute myeloid leukemia (AML), according to Novartis, the manufacturer of the multikinase inhibitor. Midostaurin is specifically recommended in the United Kingdom for use in combination with daunorubicin and cytarabine induction and high-dose cytarabine … (leggi tutto)